Medication Non-Adherence After Myocardial Infarction: An Exploration of Modifying Factors
- 628 Downloads
Medication non-adherence is a major impediment to the management of cardiovascular disease risk factors. A better understanding of the modifying factors underlying medication non-adherence among individuals with known cardiovascular disease may inform approaches for addressing non-adherence.
The purpose of this study was to identify demographic and patient characteristics, medical comorbidities, psychosocial factors, and health belief-related factors associated with medication non-adherence among patients with known cardiovascular disease.
We performed secondary analysis of baseline data from a randomized trial.
The study included 405 patients with a diagnosis of hypertension and history of acute myocardial infarction that was diagnosed within a three-year period prior to enrollment.
Baseline demographics and patient characteristics, medical comorbidities, psychosocial factors, health belief-related factors, and patient-reported medication non-adherence were analyzed.
Of 405 patients, 173 (42.7 %) reported medication non-adherence. Factors associated with non-adherence in bivariate analysis included younger age, non-white race, having less than 12 years of education, smoking, financial insecurity, identifying as nervous or tense, higher life chaos score, greater worry about having a myocardial infarction, and greater worry about having a stroke. Using multivariable modeling, we determined that age (OR 0.97 per additional year, 95 % CI, 0.95–0.99), life chaos (OR 1.06 per additional point, 95 % CI, 1.00–1.11), and worry about stroke (OR 1.12 per additional point, 95 % CI, 1.01–1.25) remained significantly associated with self-reported medication non-adherence.
We found that worry about having a stroke, higher life chaos, and younger age were all significantly associated with self-reported medication non-adherence in patients with cardiovascular disease and a history of myocardial infarction. Further research exploring these factors as targets for intervention is needed, as is additional research examining modifiable causes of medication non-adherence among patients with cardiovascular disease.
KEY WORDScardiovascular disease medication non-adherence psychosocial health beliefs
This study was supported in part by an award from the American Heart Association-Pharmaceutical Roundtable and David and Stevie Spina. Dr. Crowley is supported by a VA Health Services Research and Development Service Career Development Award (CDA 13-261), as is Dr. Zullig (CDA 13-025). Dr. Bosworth is supported by a Research Career Scientist award from the VA’s Health Services Research and Development (RCS 08-027), and has received honoraria from Takeda Pharmaceuticals, CVS/Caremark, and Sanofi Pharmaceuticals. Dr. Shah is a consultant for Castlight Health LLC, Janssen Pharmaceuticals, Cytokinetics, BMS, and Pfizer. Dr Peterson has received research grants from BMS/Sanofi, Merck/Schering, and Lilly. All other authors report no disclosures. These data have not been presented previously.
Conflict of Interest
The authors each declare that they have no conflict of interest.
- 1.Centers for Disease Control and Prevention. Heart Disease Facts. Available at: http://www.cdc.gov/heartdisease/facts.htm. Accessed June 9, 2014.
- 4.World Health Organization. Adherence to long-term therapies: evidence for action. Noncommunicable Diseases and Mental Health Adherence to long-term therapies project. http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf. Accessed June 9, 2014.
- 10.Sanfélix-Gimeno G, Peiró S, Ferreros I, et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain. J Manag Care Pharm. 2013;19(3):247–57.PubMedGoogle Scholar
- 12.Rodriguez F, Cannon CP, Steg PG, REACH Registry Investigators, et al. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol. 2013;36(12):721–7.PubMedCrossRefGoogle Scholar
- 14.Zeber JE, Manias E, Williams AF, Hutchins D, Udezi WA, Roberts CS, et al. A systematic literature review of psychosocial and behavioral factors associated with initial medication adherence: a report of the ISPOR medication adherence & persistence special interest group. Value Health. 2013;16(5):891–900.PubMedCrossRefGoogle Scholar
- 25.Feinstein A. Compliance bias and the interpretation of therapeutic trials. In: Haynes RB, Taylor D, Sackeets DL, eds. Compliance in Health Care. Baltimore: The Johns Hopkins University Press; 1979:309–22.Google Scholar